The Innovative Medicines Initiative has now launched IMI2 – Call 13.
§ Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
§ Genome-environment interactions in inflammatory skin disease
§ The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
§ Mitochondrial dysfunction in neurodegeneration
§ Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative